Blog

Reflections from AACR: The Evolving Landscape of Oncolytic Viral Therapies

Reflections from AACR: The Evolving Landscape of Oncolytic Viral Therapies

We recently attended the American Association for Cancer Research (AACR) conference. It’s the largest cancer research gathering in the U.S., and we were thrilled to present our latest results and learn from peers. Here’s a snapshot of the current developments in oncolytic viral therapies (OVTs). The State of Oncolytic Viral Therapies Diverse Targets and Approaches:Presentations at AACR showed a strong interest in OVTs, featuring 39 oncolytic viruses from 23 companies and 11 research groups. These therapies aim to combat a…

Join Us at AACR 2024: Celebrating Progress in Cancer Research

Join Us at AACR 2024: Celebrating Progress in Cancer Research

We’re thrilled to announce that we’re returning to the American Association for Cancer Research (AACR) annual meeting for the second time! It’s an honor to be invited back to this prestigious event where we’ll be showcasing our groundbreaking work in the field of cancer therapeutics. AACR is the largest gathering of cancer researchers, clinicians, survivors, and advocates in the world, with over 20,000 attendees.  Our Progress Since Last Year Last year’s experience in Orlando was unforgettable. We connected with fellow…

Engineering selective infection

Engineering selective infection

How viruses infect cells is key to developing safe oncolytic viral therapies. In this post we discuss how viruses can be engineered to target cancer cells. The infection process begins when a virus recognizes and attaches to a host cell. This attachment is typically mediated by viral proteins known as glycoproteins, which specifically bind to receptors on the surface of the target cell. These glycoproteins act like keys, unlocking the door to the cell by interacting with specific cell surface…

Regulating viral replication using RNA aptazymes

Regulating viral replication using RNA aptazymes

The biggest problem in cancer therapeutics is selectivity. Using oncolytic viral therapies, high selectivity can be achieved using the combination of selective infection and selective replication. Here, we want to address selective replication. For DNA viruses, this can be accomplished with promoters to control transcription and genome replication.  However, for RNA viruses, this does not work. A potential solution to control replication for RNA viruses is the use of aptazymes. Aptazymes are self-cleaving units composed of a riboswitch and an aptamer….

Announcing our first publication

Announcing our first publication

We are thrilled to announce the publication of Humane Genomics’ first article. We contributed a chapter to the International Review of Cell and Molecular Biology (IRCMB). This is a book series by Elsevier, as part of a special issue on Viral Vectors in Cancer Immunotherapy. Our review, titled “Rational selection of an ideal oncolytic virus to address current limitations in clinical translation,” offers valuable insights for investors, virologists, and newcomers to the field alike. In our article, we summarize the…

AACR poster session review

AACR poster session review

We were thrilled to present a poster of our work at AACR. It is one of the biggest conferences on cancer research, with 22,000 visitors. To get accepted, we had to write an abstract, which was reviewed, and we needed to be sponsored by an existing member. For us this was Dr. Sanjeev Vasudevan, whom we work with at Texas Children’s. Our poster gave a brief overview on our platform and the work we have done on Hepatoblastoma (liver cancer…

Presenting at AACR

Presenting at AACR

We are excited to announce we are presenting at the AACR annual meeting for the first time. AACR is the American Association for Cancer Research and its meeting is the largest in the world of cancer research. Last year, over 20,000 scientists, clinicians and other health care professionals, and survivors and patient advocates from around the world traveled to New Orleans. The AACR meeting for 2023 is held in Orange County Convention Center, Orlando, Florida and we have been invited…

Introduction – Brenda

Introduction – Brenda

Q: Tell me a bit about yourself Hello! My name is Brenda and I grew up in Montgomery County Maryland. I spent a lot of my weekends visiting DC going to museums and visiting monuments nearby. The National Museum of Natural History is where I first fell in love with research and it helped shape a lot of my interests and career path. The exhibits and stories they told sparked my curiosity for science and discovery. When I visit home…

Rational Design of Oncolytic Viruses

Rational Design of Oncolytic Viruses

In this post we give an overview of the history of using viruses as potential treatment for cancer. We also outline the challenges a great viral therapy needs to overcome. Last, we review our approach to rationally design and engineer safe and effective oncolytic viruses. History and current state Since the middle of the last century there has been anecdotal evidence that virus infections can help in curing or slowing down cancer. Unfortunately these infections happened randomly and the results…

Our platform

Our platform

In this post, I would like to introduce the Humane Genomics Artificial Virus Platform. Why develop an artificial virus platform? For decades, a lot of research has been conducted to see if natural viruses can be used as cancer therapeutics, with limited success. Over the last 10 years, the technology to engineer, to build viruses specifically as cancer therapeutics has matured. However, most technology approaches to make these viruses are complicated, error prone, time consuming and expensive. To address these…